Trastuzumab/Pertuzumab HercepTest companion diagnostic - Dako

Drug Profile

Trastuzumab/Pertuzumab HercepTest companion diagnostic - Dako

Alternative Names: Dako anti-her2 ihc system; HercepTest; Pertuzumab companion diagnostic - HercepTest - Dako; Trastuzumab companion diagnostic - HercepTest - Dako; Trastuzumab emtansine companion diagnostic - HercepTest - Dako

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator Dako A/S
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer

Most Recent Events

  • 21 Jun 2012 Dako A/S has been acquired by Agilent Technologies
  • 21 Oct 2010 Launched for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 21 Oct 2010 Registered for Gastric cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top